Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Lung Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

featured

Published in Lung Cancer and

Journal Scan / Research · November 17, 2020

Capmatinib in MET Exon 14–Mutated or MET-Amplified NSCLC

The New England Journal of Medicine

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Disclosure statements are available on the authors' profiles:

Sarah Goldberg MD, MPH

The New England Journal of Medicine

Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer

N. Engl. J. Med 2020 Sep 03;383(10)944-957, J Wolf, T Seto, JY Han, N Reguart, EB Garon, HJM Groen, DSW Tan, T Hida, M de Jonge, SV Orlov, EF Smit, PJ Souquet, J Vansteenkiste, M Hochmair, E Felip, M Nishio, M Thomas, K Ohashi, R Toyozawa, TR Overbeck, F de Marinis, TM Kim, E Laack, A Robeva, S Le Mouhaer, M Waldron-Lynch, B Sankaran, OA Balbin, X Cui, M Giovannini, M Akimov, RS Heist

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Lung Cancer

Capmatinib in MET Exon 14–Mutated or MET-Amplified NSCLC

Additional Info

Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer

Further Reading

Utility and Cost-Effectiveness of Multi-Gene Testing in Patients With Resected Early-Stage Lung Adenocarcinoma

Biomarkers of Disease Outcomes and Resistance Mechanisms to First-Line Osimertinib in Patients With Advanced EGFR-Mutant Lung Cancer

2022 Top Story in Oncology: Immunotherapy for the First-Line Treatment of Metastatic/Recurrent NSCLC

2022 Top Story in Oncology: Nivolumab Plus Chemotherapy for Resectable NSCLC

Association of Machine Learning–Based Assessment of Tumor-Infiltrating Lymphocytes on Histologic Images With Outcomes of Immunotherapy in Patients With NSCLC

Overall Survival With ctDNA-Guided Therapy in Advanced NSCLC

Patient-Reported Outcomes Following First-Line Lorlatinib vs Crizotinib in Patients With Advanced ALK-Positive NSCLC

Long-Term Outcomes Following Postoperative SRS vs WBRT for Resected Brain Metastasis

Long-Term Outcomes Following Pembrolizumab vs Chemotherapy as First-Line Therapy in Patients With NSCLC With PD-L1 Tumor Proportion Score ≥1%

Durvalumab With or Without Tremelimumab Plus Chemotherapy as First-Line Therapy for Metastatic NSCLC

Long-Term Survival Outcomes With Nivolumab Plus Ipilimumab vs Chemotherapy as First-Line Treatment for Metastatic NSCLC

Recently Updated